"Tumor Immunology Meets Oncology" (TIMO), 22 May-24 May 2025 in Brandenburg an der Havel, Germany [0.03%]
肿瘤免疫学与肿瘤学会议（TIMO），2025年5月22日至24日在德国勃兰登堡举行
Barbara Seliger
Barbara Seliger
The "Tumor Immunology Meets Oncology" (TIMO XIX) meeting 2025 reports on the rapidly growing field of basic, but in particular translational tumor immunology thereby providing deeper insights into the heterogeneity of tumors, their microenv...
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC) [0.03%]
Durvalumab联合顺铂-依托泊苷一线治疗广泛期大型肺类癌(aLCNEC)的II期研究
Elizabeth Dudnik,Hovav Nechushtan,Ofer Rotem et al.
Elizabeth Dudnik et al.
Background: LCNEC is a rare high-grade neuroendocrine malignancy with poor prognosis and limited evidence to guide systemic therapy. Methods: ...
Efficacy and safety of anti-PD-1-based therapies in advanced melanoma across acral and mucosal subtypes: a nationwide retrospective cohort study [0.03%]
抗PD-1疗法治疗肢端和黏膜型黑色素瘤的有效性和安全性：全国队列回顾性研究
Yuan Qiao,Xiao Fu,Iltaf Hussain et al.
Yuan Qiao et al.
Background: Acral melanoma (AM) and mucosal melanoma (MM) respond poorly to anti-PD-1 monotherapy. Therefore, there is an urgent need to explore safe and effective anti-PD-1-based combined therapies. ...
Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lung cancer [0.03%]
吸烟相关肠道菌群的改变影响非小细胞肺癌免疫检查点抑制剂治疗效果
Po-Yu Chien,Wen-Chien Cheng,Chin-Chuan Hung et al.
Po-Yu Chien et al.
Background: Smoking status has been associated with differences in immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC), though the underlying mechanisms remain unclear. This prospective cohort...
Restoring STING expression in soft tissue sarcoma increases activation and function of tumor-infiltrating lymphocytes [0.03%]
恢复软组织肉瘤中的STING表达可增加肿瘤浸润淋巴细胞的活化和功能
Stine Høvring Godsk,Mireia Crus De Los Santos,Tobias Wang Bjerg et al.
Stine Høvring Godsk et al.
Sarcomas are rare, highly heterogeneous malignancies, with soft tissue sarcomas (STS) comprising nearly 80 histological subtypes. Localized STS is generally treated with surgery and radiotherapy, whereas metastatic disease relies largely on...
Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy [0.03%]
用于治疗骨肉瘤的免疫刺激载荷型溶瘤病毒
Sumbul Khan,Theresa A Higgins,Isabella Shimko-Lofano et al.
Sumbul Khan et al.
Osteosarcoma (OS) is a highly aggressive bone malignancy that predominantly affects children and young adults. There have been no major changes in patient survival in the past four decades. Therefore, new therapeutic interventions are neede...
Single-cell and multi-omics integration delineates the landscape of gene-wise intratumor heterogeneity and identifies prognostic biomarkers for immunotherapy in non-small cell lung cancer [0.03%]
单细胞及多组学整合解析非小细胞肺癌基因水平的异质性并鉴定免疫治疗预后标志物
Jianye Yuan,Zelin Weng,Zhenguo Li et al.
Jianye Yuan et al.
Background: Gene-wise intratumor heterogeneity (ITH), defined as spatial variability in the expression of individual genes across tumor regions, remains incompletely characterized in non-small cell lung cancer (NSCLC). Id...
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies [0.03%]
一项I期研究：评估单克隆抗体细胞程序性死亡蛋白-1(PD-1)抑制剂塞特利马b(Cetrelimab, JNJ-63723283)注射液在晚期实体瘤受试者中的药代动力学、安全性和初步疗效
Piotr Rutkowski,Dariusz M Kowalski,Victor Moreno et al.
Piotr Rutkowski et al.
Purpose: Pharmacokinetics, pharmacodynamics, safety, and efficacy of subcutaneous cetrelimab were assessed in Parts (P)3 and 4 of the phase I LUC1001 study in patients with advanced/refractory solid tumors who progressed ...
Impact of PD-1+Tim-3+CD8+ T cells in pretreatment tumors on chemotherapy responses in esophageal cancer [0.03%]
食管癌治疗前肿瘤中PD-1+Tim-3+CD8+ T细胞对化疗的反应的影响
Tomoko Sumimoto,Kei Yamamoto,Takuro Saito et al.
Tomoko Sumimoto et al.
While chemotherapy has traditionally been recognized for its direct cytotoxic effects on cancer cells, increasing attention has been directed towards its capability to modulate tumor immune mechanisms. However, the majority of studies have ...
Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma [0.03%]
Bintrafusp阿尔法治疗复发或转移性嗅神经母细胞瘤患者的疗效
Nyall R London Jr,Dara Bracken-Clarke,Elisabetta Xue et al.
Nyall R London Jr et al.
Background: There is no established treatment for patients with recurrent/metastatic (R/M) olfactory neuroblastoma (ONB), a rare sinonasal tumor. We conducted the first immunotherapy clinical trial (NCT05012098) in patien...